GHRP-2 (Pralmorelin)
A reference guide to GHRP-2, the synthetic growth hormone secretagogue studied for its action at the ghrelin receptor and its role in growth hormone secretion. Written for a laboratory and research-use-only context in Australia.
What GHRP-2 is
GHRP-2 is a synthetic peptide belonging to the family known as growth hormone secretagogues. In the scientific literature it also appears under the names pralmorelin and KP-102. It was one of the earliest members of the growth hormone releasing peptide (GHRP) series to be characterised, and it is studied as a laboratory tool for probing how the body regulates the release of growth hormone. In a research context it is described as a ghrelin mimetic, meaning it acts at the same receptor as the naturally occurring hormone ghrelin.
Structurally, GHRP-2 is a short hexapeptide, a chain of six amino acids, with a molecular weight of roughly 817.9 grams per mole. It is supplied to laboratories as a lyophilised (freeze dried) powder that is reconstituted into solution before it is handled in study protocols. Its small, defined structure and well documented receptor activity are the reasons it has remained a useful reference compound in growth hormone axis research for several decades.
- Class: synthetic growth hormone secretagogue and ghrelin receptor agonist.
- Synonyms: pralmorelin, KP-102, GHRP-2.
- Composition: a hexapeptide, six amino acids in a defined sequence.
- Molecular weight: approximately 817.9 grams per mole.
- Physical form: white lyophilised powder, reconstituted for research use.
- Receptor family studied: the growth hormone secretagogue receptor, GHS-R1a.
Everything on this page describes GHRP-2 as it is studied in laboratory and research settings. It is not a description of use in people, and nothing here is medical, dosing or administration guidance. GHRP-2 is not approved by the TGA for human use and is supplied in Australia for research use only.
Mechanism of action and receptor targets
GHRP-2 is studied as an agonist of the growth hormone secretagogue receptor type 1a, abbreviated GHS-R1a. This is the same receptor that binds ghrelin, the endogenous peptide sometimes described in research as the hunger hormone. The receptor is expressed on the somatotroph cells of the anterior pituitary gland and in regions of the hypothalamus, which places GHRP-2 at the centre of the pathway that controls how and when growth hormone is released.
When GHRP-2 binds GHS-R1a in research models, it activates a Gq protein coupled cascade involving phospholipase C, inositol trisphosphate and the mobilisation of intracellular calcium. In pituitary cells this signalling drives the release of stored growth hormone. GHRP-2 is also studied for a dual action at the level of the hypothalamus, where it appears to amplify the effect of growth hormone releasing hormone (GHRH) while reducing the inhibitory tone of somatostatin. This combination is why researchers describe GHRP-2 and GHRH as acting synergistically on growth hormone output.
- Receptor: GHS-R1a, the ghrelin receptor, is the primary molecular target studied.
- Signal pathway: Gq protein, phospholipase C, IP3 and intracellular calcium release.
- Site one: somatotroph cells of the anterior pituitary, where growth hormone is stored.
- Site two: the hypothalamus, where GHRH and somatostatin balance is modulated.
- Synergy: studied to potentiate GHRH driven growth hormone release.
- Downstream: growth hormone release is linked in research to the IGF-1 axis.
At higher exposures in research models, GHS-R1a agonists including GHRP-2 have been observed to influence prolactin, ACTH and cortisol signalling. These cross effects are themselves an active area of receptor pharmacology study rather than an intended outcome, and they are described here only as observed research findings.
What GHRP-2 is studied for
GHRP-2 is used in research primarily as a probe of the somatotropic axis, the network of signals that governs growth hormone secretion. Because it produces a defined, measurable release of growth hormone through a well characterised receptor, it is a convenient tool for investigators asking questions about how that axis is switched on, how it is regulated, and how it changes across different experimental conditions.
- Growth hormone secretion: how a GHS-R1a agonist triggers release from pituitary somatotrophs.
- Ghrelin receptor pharmacology: characterising GHS-R1a binding, signalling and desensitisation.
- GHRH synergy: how combined stimulation with GHRH shapes the size and shape of a growth hormone pulse.
- Growth hormone pulsatility: the timing and amplitude of secretory pulses under a secretagogue.
- Appetite and energy balance: ghrelin pathway signalling and food intake in animal research models.
- Comparative potency: benchmarking GHRP-2 against other secretagogues such as GHRP-6, hexarelin and ipamorelin.
- Diagnostic pharmacology: its historical role in tests of pituitary growth hormone reserve.
It is important to frame all of these as questions the compound helps researchers investigate, not as outcomes offered to a person. GHRP-2 is a reagent used to interrogate a biological pathway in a controlled study, and the research value lies in what its predictable receptor activity reveals about that pathway.
GHRP-2 is described here strictly in terms of the biology it is used to study. NovaPeptides makes no claim that GHRP-2 treats, cures, prevents or improves any condition in humans, and offers no performance, cosmetic or body composition claims of any kind. It is a research compound only.
The research landscape
GHRP-2 sits within a well studied lineage of growth hormone releasing peptides that trace back to the original GHRP-6 work of the 1980s. Under the name pralmorelin, GHRP-2 has a documented history in diagnostic pharmacology, where it was investigated and, in Japan, developed as an agent for assessing the growth hormone secretory capacity of the pituitary. That diagnostic heritage is one reason its receptor activity and secretory profile are so thoroughly described in the literature.
Within the secretagogue family, researchers frequently compare GHRP-2 with its relatives. It is generally characterised as more potent at stimulating growth hormone release than GHRP-6, while producing a weaker appetite signal than GHRP-6 in comparative models. Against ipamorelin, which is studied as a highly selective secretagogue, GHRP-2 is described as broader in its receptor effects. These comparisons are exactly the kind of structure and activity relationships that make the GHRP series a productive area of study.
Comparative secretagogue research is not about ranking compounds for use. It is about understanding how small changes in peptide structure change receptor selectivity, signalling strength and secondary effects. GHRP-2 is a valuable reference point in that map because its behaviour is so well documented.
How GHRP-2 is handled in a research setting
GHRP-2 is supplied as a lyophilised powder because peptides are most stable in a dry state. In a laboratory it is reconstituted into solution before it can be measured or studied, and the general handling principles below are the same ones that apply to most research peptides. These are described as standard laboratory practice, not as instructions for use in any living subject.
- Lyophilised storage: the sealed dry powder is typically held frozen, around minus 20 degrees C, and protected from light and moisture.
- Reconstitution: bacteriostatic water is the established diluent used to bring lyophilised research peptides into solution.
- Reconstituted storage: solutions are generally refrigerated at 2 to 8 degrees C and used within a limited window that varies by sequence.
- Freeze thaw: repeated freezing and thawing of a reconstituted solution is avoided because it can degrade peptide integrity.
- Aliquoting: dividing a stock into smaller working portions limits repeated handling of the main supply.
- Mass balance and records: net peptide content and careful record keeping support reproducible measurements.
- Analytical checks: purity and identity are confirmed against the batch Certificate of Analysis before work begins.
The points above describe how a research compound is stored, reconstituted and measured in a laboratory. They are general handling principles for study materials and are not guidance for administration to humans or animals outside an approved research protocol.
Sourcing, purity and verification
In peptide research, results are only as reliable as the material behind them. A sample that is impure, mislabelled or degraded produces data that cannot be trusted or reproduced. This is why verification matters so much, and why a credible Certificate of Analysis (COA) is the single most important document that accompanies a research peptide. The COA is the evidence that what is printed on the label is what is actually in the vial.
- Purity by RP-HPLC: reverse phase high performance liquid chromatography quantifies how much of the sample is the target peptide, commonly reported as a percentage.
- Identity by mass spectrometry: confirms the measured molecular weight matches the expected structure of GHRP-2.
- Appearance and description: the physical state of the lyophilised material.
- Net peptide content: the actual peptide mass, which supports accurate quantitative work.
- Batch traceability: a lot number that ties the certificate to the specific vial in hand.
A verified COA from an independent testing pathway removes guesswork. Rather than trusting a supplier claim, a researcher can read the chromatography and mass spectrometry results directly and confirm the identity and purity of the exact batch they are working with. GHRP-2 supplied by NovaPeptides carries a verified Novagen Certificate of Analysis for this reason.
Why researchers source GHRP-2 from NovaPeptides
NovaPeptides is an Australian owned business based on the Gold Coast that has supplied research peptides to Australian researchers for over three years. That track record matters in a field where consistency, correct labelling and reliable batch documentation separate a usable research material from a wasted experiment. Sourcing domestically also means shorter transit, local support and material that has been handled with the Australian research context in mind.
- Australian owned and Gold Coast based, with local support and dispatch.
- Over three years supplying research peptides to Australian researchers.
- A verified Novagen Certificate of Analysis on every batch, with purity and identity data.
- Lyophilised material prepared and labelled for a laboratory and research-use-only context.
- Clear research-use-only framing with no medical, dosing or performance claims.
Every batch of GHRP-2 is supplied with a verified Novagen Certificate of Analysis, so researchers can confirm purity and identity for the specific lot they receive rather than relying on a generic specification sheet.
Research-use status in Australia
GHRP-2 is not approved by the Therapeutic Goods Administration (TGA) for human use. It is supplied in Australia strictly for laboratory and research use only. It is not a medicine, not a supplement and not a cosmetic, and it is not intended for human or veterinary administration. It is intended to be handled by qualified researchers within appropriate laboratory settings and study protocols.
NovaPeptides supplies GHRP-2 on this basis and makes no therapeutic, diagnostic, cosmetic or performance claims about it in relation to people. All of the receptors, pathways and research areas described on this page relate to how GHRP-2 is studied as a research compound, not to any outcome offered to an individual. Buyers are responsible for ensuring their intended research use complies with all applicable Australian laws, institutional requirements and ethical approvals.
GHRP-2 is not TGA approved for human use and is supplied for laboratory and research use only. It is not for human or animal consumption, and nothing on this page should be read as encouraging such use.
Frequently asked questions
What is GHRP-2?+
GHRP-2, also known as pralmorelin or KP-102, is a synthetic hexapeptide in the growth hormone secretagogue family. In research it acts as an agonist at the ghrelin receptor, GHS-R1a, and is studied as a laboratory tool for investigating how growth hormone is released. It is supplied for research use only and is not approved by the TGA for human use.
How does GHRP-2 work in research models?+
GHRP-2 binds the growth hormone secretagogue receptor GHS-R1a on pituitary and hypothalamic cells. This activates a phospholipase C and calcium signalling cascade that drives growth hormone release from the pituitary. It is also studied for amplifying the effect of GHRH and reducing somatostatin tone, which is why researchers describe it as acting synergistically with GHRH on growth hormone output.
What is GHRP-2 studied for?+
It is studied mainly as a probe of the growth hormone axis: how a ghrelin receptor agonist triggers growth hormone secretion, how growth hormone pulses are shaped, ghrelin receptor pharmacology, appetite and energy balance signalling in animal models, and comparative potency against other secretagogues. These are research questions the compound helps investigate, not outcomes offered to a person.
Is GHRP-2 the same as pralmorelin?+
Yes. Pralmorelin is another name for GHRP-2, and it also appears in the literature as KP-102. Under the pralmorelin name it has a documented history in diagnostic pharmacology, where it was investigated as an agent for assessing the growth hormone secretory capacity of the pituitary.
What is the difference between GHRP-2 and GHRP-6?+
Both are growth hormone releasing peptides that act at the ghrelin receptor. In comparative research, GHRP-2 is generally characterised as more potent at stimulating growth hormone release than GHRP-6, while producing a weaker appetite signal than GHRP-6. These differences make the two useful reference points when researchers study structure and activity relationships across the secretagogue family.
How does GHRP-2 differ from ipamorelin?+
Ipamorelin is studied as a highly selective growth hormone secretagogue with minimal effect on other hormones, whereas GHRP-2 is described in research as having broader receptor effects, including observed influences on prolactin, ACTH and cortisol at higher exposures. Comparing the two helps researchers understand how peptide structure changes receptor selectivity.
How is GHRP-2 stored and handled in a laboratory?+
As a lyophilised powder it is typically kept frozen, around minus 20 degrees C, and protected from light and moisture. It is reconstituted with bacteriostatic water for study, and the resulting solution is generally refrigerated at 2 to 8 degrees C and used within a limited window. Repeated freeze thaw cycles are avoided to preserve peptide integrity. These are general handling principles, not administration guidance.
Is GHRP-2 approved or legal in Australia?+
GHRP-2 is not approved by the TGA for human use. It is supplied in Australia strictly for laboratory and research use only, and it is not a medicine, supplement or cosmetic. Buyers are responsible for ensuring their intended research use complies with all applicable Australian laws, institutional requirements and ethical approvals.
How can researchers verify the purity of GHRP-2?+
Through the Certificate of Analysis. A credible COA reports purity by reverse phase HPLC and confirms identity by mass spectrometry against the expected molecular weight, along with a batch or lot number for traceability. NovaPeptides supplies GHRP-2 with a verified Novagen Certificate of Analysis so purity and identity can be confirmed for the specific batch received.
Where can researchers buy GHRP-2 in Australia?+
NovaPeptides is an Australian owned, Gold Coast based supplier that has provided research peptides to Australian researchers for over three years. GHRP-2 is supplied as a lyophilised research compound with a verified Novagen Certificate of Analysis on every batch, for laboratory and research use only.
Does GHRP-2 affect appetite in research?+
Because GHRP-2 acts at the ghrelin receptor, the same receptor involved in hunger signalling, it is studied in animal models for effects on food intake and energy balance. In comparative research its appetite signal is generally weaker than that of GHRP-6. This is described as an observed research finding within the ghrelin pathway, not an effect offered to a person.
Questions? Talk to us.
Message us on WhatsApp and we will walk you through the kits, the COAs, reconstitution and the dose tool.
Chat with us on WhatsApp